Fluoride-free cavity fighter?
This article was originally published in The Tan Sheet
Executive Summary
Ortek Therapeutics has "begun its formal pursuit" of new drug applications for two new Rx products containing CaviStat, a cavity-fighting complex that mimics saliva's anti-cavity properties, the firm says July 11. Cavistat contains arginine, the common amino acid that neutralizes erosive acids while strengthening and repairing the tooth structure with calcium carbonate and bicarbonate, the firm states. Ortek hopes to have DenClude Desensitizing Dental Cream approved as the first flouride-free cavity fighting toothpaste in the world. The product already is an Rx toothpaste indicated for the management of tooth sensitivity. The firm also is pursuing approval of BasicMints as the first cavity-fighting confection available to consumers worldwide. While fluoride helps to remineralize teeth, it can have toxic side effects and lead to bone fractures after prolonged use, Ortek maintains. The firm says it will eventually pursue OTC status for the products...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.